The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based tests to inform decisions about adjuvant chemotherapy for patients with a certain type of breast cancer, i.e., first-time, hormone receptor-positive and HER2/neu-negative breast cancer.